UK-based Arecor Therapeutics (AIM: AREC) has announced that it is to acquire Tetris Pharma.
Anglo-Dutch firm Tetris is a commercial stage pharma company with a sales and distribution team and a platform focused on injectable speciality products across the UK and Europe.
The company has an exclusive supply agreement and license to sell the first stable liquid ready-to-use glucagon auto-injector pen, Ogluo (glucagon), within the European Economic Area, UK and Switzerland.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze